Hear from Allison Moore, Founder/CEO of the Hereditary Neuropathy Foundation about the past, present and future or CMT research.
Stay tuned: Phase 2 Study results to be released late Summer 2025! HNF’s Wearable Tech...
Seeking Participants for a New CMT Clinical Trial (for the US only): A Chance to Help Advance...
A recent clinical trial has shown promising results for a new treatment option for people living...
Join the thousands of HNF volunteers who are fueling CMT research. The more you share, the more we’ll learn. Complete your GRIN surveys today!
HNF Awards the inaugural HNF Clinical Translation Fellowship in the amount of $170,000 to Kayla...
Research Opportunity: CMT-SORD I am writing to you today because there is a research opportunity...
Digital Health Technologies for Charcot-Marie-Tooth (CMT) DiseasePatients attending the Clinical...
The INSPIRE trial is a Phase 3 double-blind placebo-controlled registrational study evaluating the effect of once-daily (QD) oral govorestat (AT-007) in 56 patients aged 16-55 with SORD Deficiency in the US and Europe.
HNF Contributes CMTRN Data to C-Path’s RDCA-DAP, Strengthening Research Capabilities for Inherited...
HNF is thrilled to announce that we have been accepted to host a 1-hour panel discussion during the Bio International Convention in San Diego, CA, in June 2024.
0 Comments